FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

CGMP Violations at Zhejiang Easyclean

FDA warns Chinas Zhejiang Easyclean Daily Chemical Co. about CGMP violations in its production of finished drugs.

Medical Devices

FDA Drops LDT Regulation, Looks to RUOs: Attorneys

Two Hyman, Phelps & McNamara attorneys say FDA may give research-use-only products greater regulatory scrutiny as a way to maintain some level of cont...

latest-news-card-1
Biologics

CBERs Prasad Outlines Rare Disease Goals

CBER director Vinay Prasad outlines his expectations for advancing rare disease products, such as embracing both surrogate endpoints for accelerated a...

latest-news-card-1
Human Drugs

Nubega OKd as Single Agent in Prostate Cancer

FDA approves a Bayer Healthcare Pharmaceuticals supplemental NDA for Nubega (darolutamide) for metastatic castration-sensitive prostate cancer.

Biologics

Moderna Wins OK for Next-Gen Covid Vaccine

FDA approves Modernas next-generation Covid-19 vaccine, Nexspike (mRNA-1283), for use in all adults 65 and older, and individuals aged 12-64 years wit...

latest-news-card-1
Human Drugs

Appeals Court Halts Federal Layoffs

A federal appeals court upholds a freeze on layoffs across FDA and other major federal agencies, rejecting an effort by the Trump administration to li...

Medical Devices

Improved Swoop Portable Brain MRI Cleared

FDA clears a Hyperfine 510(k) for its next-generation AI-powered portable MRI system for the brain, the Swoop system.

latest-news-card-1
FDA General

FDA Launches Elsa AI Tool for Efficiencies

FDA launches a generative Artificial Intelligence tool called Elsa that is designed to help employees from scientific reviewers to investigators wor...

latest-news-card-1
Human Drugs

Bipartisan Push Seeks Boost in ALS Research

Congressman Jason Crow (D-CO) leads a bipartisan group of lawmakers in a push to significantly expand federal funding for Amyotrophic Lateral Sclerosi...

latest-news-card-1
Human Drugs

Enhertu Combo Delays Breast Cancer Progression

A new combination therapy involving AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) and pertuzumab (Genentechs Perjeta) shows signifi...